Literature DB >> 16647882

Integration bias of gammaretrovirus vectors following transduction and growth of primary mouse hematopoietic progenitor cells with and without selection.

Mari Aker1, Julie Tubb, Daniel G Miller, George Stamatoyannopoulos, David W Emery.   

Abstract

The recent recognition that recombinant retrovirus vectors can induce oncogenic transformation has stimulated much interest in the pattern of vector integration sites. We report here on the integration pattern of a gammaretrovirus reporter vector following transduction and ex vivo culture of primary mouse bone marrow progenitor cells in the absence and presence of drug selection. Using a novel method of cloning junction fragments, we observed no bias for integrations within genes, but did observe a bias for integrations within gene-dense regions and especially near transcriptional start sites of highly active genes, similar to previous reports in other cell types. We also document a novel bias for integrations within or near a class of genes that encode nuclear-localized proteins. We found that drug selection resulted in an increase in the frequency of recovered integration events that were located within the beginning of genes, integration events that were located in less gene-dense regions, and integration events that were oriented in an antisense direction relative to flanking gene transcription. Taken together, these studies provide new insights into the nature of retrovirus vector integration patterns in primary cells and demonstrate that selection based on vector expression can bias the integration site repertoire.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647882     DOI: 10.1016/j.ymthe.2006.02.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  Gammaretroviral vector integration occurs overwhelmingly within and near DNase hypersensitive sites.

Authors:  Mingdong Liu; Chang Long Li; George Stamatoyannopoulos; Michael O Dorschner; Richard Humbert; John A Stamatoyannopoulos; David W Emery
Journal:  Hum Gene Ther       Date:  2011-12-14       Impact factor: 5.695

2.  Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator.

Authors:  Chang Long Li; Ding Xiong; George Stamatoyannopoulos; David W Emery
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

3.  The sea urchin sns5 insulator protects retroviral vectors from chromosomal position effects by maintaining active chromatin structure.

Authors:  Danilo D'Apolito; Elena Baiamonte; Mariella Bagliesi; Rosalba Di Marzo; Roberta Calzolari; Leda Ferro; Vito Franco; Giovanni Spinelli; Aurelio Maggio; Santina Acuto
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454

Review 4.  The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors.

Authors:  David W Emery
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

5.  Bidirectional Retroviral Integration Site PCR Methodology and Quantitative Data Analysis Workflow.

Authors:  Gajendra W Suryawanshi; Song Xu; Yiming Xie; Tom Chou; Namshin Kim; Irvin S Y Chen; Sanggu Kim
Journal:  J Vis Exp       Date:  2017-06-14       Impact factor: 1.355

6.  Retroviral integration site selection.

Authors:  Sébastien Desfarges; Angela Ciuffi
Journal:  Viruses       Date:  2010-01-12       Impact factor: 5.818

7.  HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP.

Authors:  Kiran N Meekings; Jeremy Leipzig; Frederic D Bushman; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2008-03-21       Impact factor: 6.823

8.  Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy.

Authors:  Theodore S Nowicki; Colin Farrell; Marco Morselli; Liudmilla Rubbi; Katie M Campbell; Mignonette H Macabali; Beata Berent-Maoz; Begoña Comin-Anduix; Matteo Pellegrini; Antoni Ribas
Journal:  Cancer Discov       Date:  2020-07-22       Impact factor: 38.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.